Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Capital Expenditures (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Capital Expenditures for 16 consecutive years, with $350.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 99.78% year-over-year to $350.0, compared with a TTM value of $6644.0 through Oct 2025, down 95.84%, and an annual FY2025 reading of $6644.0, down 95.84% over the prior year.
  • Capital Expenditures was $350.0 for Q4 2025 at Pharma-Bio Serv, down from $2036.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $157015.0 in Q4 2024 and bottomed at -$6237.0 in Q4 2021.
  • Average Capital Expenditures over 5 years is $11985.4, with a median of $2087.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures crashed 198.67% in 2021, then soared 10037.66% in 2024.
  • Year by year, Capital Expenditures stood at -$6237.0 in 2021, then surged by 294.6% to $12137.0 in 2022, then crashed by 113.02% to -$1580.0 in 2023, then skyrocketed by 10037.66% to $157015.0 in 2024, then tumbled by 99.78% to $350.0 in 2025.
  • Business Quant data shows Capital Expenditures for PBSV at $350.0 in Q4 2025, $2036.0 in Q3 2025, and $4258.0 in Q2 2025.